Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
than 70% of men with (CardiovascularDisease) CVD and sharing a myriad of risk factors like hypertension, smoking, diabetes, obesity, ageing and the metabolic syndrome. Diabetes increases the risk of both ED and CVD with the latter being the leading cause of death. Endothelial dysfunction and its role in the development of atherosclerosis may be the common link between ED, CVD and diabetes. With the current epidemic of type 2 diabetes, diabetes related CVD will increase in tandem. Early (...) Association Between Erectile Dysfunction and CardiovascularDisease: A Systematic Review Association Between Erectile Dysfunction and CardiovascularDisease: A Systematic Review | Chattagram Maa-O-Shishu Hospital Medical College Journal Search / / / Review Articles Keywords: ED; CVD; Risk factors Abstract Erectile Dysfunction (ED) describes the persistent inability to achieve or maintain a penile erection for adequate sexual performance. ED is thought to be a vascular disease affecting more
Systematic review of the prospective association of daily step counts with risk of mortality, cardiovasculardisease, and dysglycemia Systematic review of the prospective association of daily step counts with risk of mortality, cardiovasculardisease, and dysglycemia | International Journal of Behavioral Nutrition and Physical Activity | Full Text Search Search all BMC articles Search Systematic review of the prospective association of daily step counts with risk of mortality, cardiovascular (...) disease, and dysglycemia , , , , , , , , , , , , , , & volume 17 , Article number: 78 ( 2020 ) 3866 Accesses 7 Citations 174 Altmetric Abstract Background Daily step counts is an intuitive metric that has demonstrated success in motivating physical activity in adults and may hold potential for future public health physical activity recommendations. This review seeks to clarify the pattern of the associations between daily steps and subsequent all-cause mortality, cardiovasculardisease (CVD) morbidity
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS).To determine whether switching to ticagrelor monotherapy after 3 (...) with ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The incidence of major adverse cardiac and cerebrovascular events was not significantly different between the ticagrelor monotherapy after 3-month DAPT group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% CI, 0.45 to 1.06]; P = .09).Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor
Strategies For Risk Reduction and Management of Older Adults With CardiovascularDisease During the COVID-19 Pandemic Strategies For Risk Reduction and Management of Older Adults With CardiovascularDisease During the COVID-19 Pandemic - American College of Cardiology ') Search All Types Search or Menu . This article was authored by Nicole M. Orr, MD, FACC , and the Geriatric Cardiology Council. Share via: Clinical Topics: Keywords: Aged, SARS Virus, Angiotensin Receptor Antagonists (...) , Hydroxychloroquine, Mineralocorticoid Receptor Antagonists, Caregivers, Angiotensin-Converting Enzyme Inhibitors, COVID-19, Coronavirus, Coronavirus Infections, Neprilysin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neprilysin, Chloroquine, Subacute Care, Social Isolation, Skilled Nursing Facilities, CardiovascularDiseases > > Strategies For Risk Reduction and Management of Older Adults With CardiovascularDisease During the COVID-19 Pandemic Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext
Covid-19 and cardiovasculardisease. Guideline: Diagnosis and management of cardiovasculardisease during the covid-19 pandemicPublished by the European Society of Cardiology.This summary is based on the version published on 21 April 2020 (https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance).Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing
Variations between women and men in risk factors, treatments, cardiovasculardisease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Some studies, mainly from high-income countries (HICs), report that women receive less care (investigations and treatments) for cardiovasculardisease than do men and might have a higher risk of death. However, very few studies systematically report risk factors, use of primary or secondary (...) prevention medications, incidence of cardiovasculardisease, or death in populations drawn from the community. Given that most cardiovasculardisease occurs in low-income and middle-income countries (LMICs), there is a need for comprehensive information comparing treatments and outcomes between women and men in HICs, middle-income countries, and low-income countries from community-based population studies.In the Prospective Urban Rural Epidemiological study (PURE), individuals aged 35-70 years from urban
to alter dietary fats and achieving a reduction in saturated fat; 3) compared with higher saturated fat intake or usual diet; 4) not multifactorial; 5) in adult humans with or without cardiovasculardisease (but not acutely ill, pregnant or breastfeeding); 6) intervention duration at least 24 months; 7) mortality or cardiovascular morbidity data available.Two review authors independently assessed inclusion, extracted study data and assessed risk of bias. We performed random-effects meta-analyses, meta (...) Reduction in saturated fat intake for cardiovasculardisease. Reducing saturated fat reduces serum cholesterol, but effects on other intermediate outcomes may be less clear. Additionally, it is unclear whether the energy from saturated fats eliminated from the diet are more helpfully replaced by polyunsaturated fats, monounsaturated fats, carbohydrate or protein.To assess the effect of reducing saturated fat intake and replacing it with carbohydrate (CHO), polyunsaturated (PUFA
searched MEDLINE, OVID databases, SCOPUS, and medrxiv.org for the period December 1, 2019, to May 1, 2020. The outcome of interest was the risk of COVID-19 mortality in patients with and without pre-existing conditions. Comorbidities explored were cardiovasculardiseases (coronary artery disease, hypertension, cardiac arrhythmias, and congestive heart failure), chronic obstructive pulmonary disease, type 2 diabetes, cancer, chronic kidney disease, chronic liver disease, and stroke. Two independent (...) The association of cardiovasculardisease and other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis The association of cardiovasculardisease and other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis | medRxiv Search for this keyword The association of cardiovasculardisease and other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis Paddy Ssentongo , Anna E. Ssentongo
Plasma PCSK9 concentrations predict Cardiovascular Events in subjects free of vascular disease and with stable coronary artery disease: Findings from a community-based prospective study and a meta-analysis Plasma PCSK9 concentrations predict Cardiovascular Events in subjects free of vascular disease and with stable coronary artery disease: Findings from a community-based prospective study and a meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary (...) version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Plasma PCSK9 concentrations predict Cardiovascular Events in subjects free of vascular disease and with stable coronary artery disease: Findings from
Protocol for a systematic review of qualitative and quantitative effects of cardiovasculardisease risk communication using heart age concepts Protocol for a systematic review of qualitative and quantitative effects of cardiovasculardisease risk communication using ‘heart age’ concepts | medRxiv Search for this keyword Protocol for a systematic review of qualitative and quantitative effects of cardiovasculardisease risk communication using ‘heart age’ concepts Carissa Bonner , Carys Batcup (...) of Public Health, Faculty of Medicine and Health , Sydney, New South Wales, Australia Abstract Introduction The concept of ‘heart age’ is increasingly used for health promotion and alongside clinical guidelines for cardiovasculardisease (CVD) prevention. These tools have been used by millions of consumers around the world, and many health organisations promote them as a way of encouraging lifestyle change. However, heart age tools vary widely in terms of their underlying risk models and display formats
Chelation therapy for atherosclerotic cardiovasculardisease. Chelation therapy is promoted and practiced around the world as a form of alternative medicine in the treatment of atherosclerotic cardiovasculardisease. It has been suggested as a safe, relatively inexpensive, non-surgical method of restoring blood flow in atherosclerotic vessels. However, there is currently limited high-quality, adequately-powered research informing evidence-based medicine on the topic, specifically regarding (...) with atherosclerotic cardiovasculardisease. The main outcome measures we considered include all-cause or cause-specific mortality, non-fatal cardiovascular events, direct or indirect measurement of disease severity, and subjective measures of improvement or adverse events.Two review authors independently extracted data and assessed trial quality using standard Cochrane procedures. A third author considered any unresolved issues, and we discussed any discrepancies until a consensus was reached. We contacted study
Palliative Care Considerations For Patients With CardiovascularDisease Under COVID-19 Palliative Care Considerations For Patients With CardiovascularDisease Under COVID-19 - American College of Cardiology ') Search All Types Search or Menu CBT=cognitive behavioral therapy; IV=intravenous; po=by mouth; SL=sublingually + People with Parkinsonism, Lewy body disease or pre-existing cogwheel rigidity, for whom haloperidol is contraindicated, quetiapine 12.5-25 mg orally up to 4 times daily can (...) to the surge in deaths in most communities. Bereavement support and acknowledgement of both our loss as clinicians, and the family's loss should be routine after a death. Provider Resiliency The cardiovascular care team is immersed on the front lines preparing for the surge of COVID-19 patients or already deeply engaged depending on location. Usual stress and long hours have been superseded by novel adversaries. Clinicians work lacking PPE in a new environment, with risks of COVID-19 illness and mortality
SQC Approval Date: April 24, 2020 Patients with cardiovascularconditions, especially poorly controlled disease, are at higher risk for COVID-19 complications. As such, they should be counseled to avoid situations that would put them at risk for SARS CoV2 exposure. They, along with their physician, should evaluate their workplace and determine if undue risk exists. If so, mitigation strategies should be considered. These include minimizing face-to-face contact between employees, assigning work (...) Syndrome X, Angina, Stable, Heart Defects, Congenital, Dyslipidemias, Geriatrics, Heart Failure, Angiography, Diagnostic Imaging, Pericarditis, Secondary Prevention, Hypertension, Pulmonary, Sleep Apnea Syndromes, Sports, Angina, Stable, Exercise Test, Heart Valve Diseases, Aneurysm, COVID-19, Coronavirus, Coronavirus Infections, Cardiology Magazine, ACC Publications > > Feature | Key Questions on COVID-19 and CardiovascularDisease Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext. 5603
Position Statement on Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic CardiovascularDisease During the COVID-19 Pandemic 1 Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic CardiovascularDisease During the COVID-19 Pandemic: A Position Statement by the Cardiac Society of Australia and New Zealand Stephen J Nicholls 1 , Mark Nelson 2 , Carolyn Astley 3 , Tom Briffa 4 , Alex Brown 5 , Robyn Clark 3 , David Colquhoun 6 , Robyn Gallagher (...) care across the world. In addition to the described cardiovasculardisease (CVD) complications of COVID-19, including myocarditis, myocardial injury, arrhythmia and thromboembolism, the pandemic has additional implications for the management of the patient with established atherosclerotic CVD. In particular, it provides challenges for the use and introduction of secondary prevention measures. This position statement provides recommendations for effective delivery of secondary prevention strategies
Abstract Introduction: The Coronavirus-19 disease (COVID-19) pandemic is caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pre-existing cardiovasculardisease (CVD) increases the morbidity and mortality of COVID-19, and COVID-19 itself causes serious cardiac sequelae. Strategies to minimise the risk of viral transmission to healthcare workers and uninfected cardiac patients while prioritising high quality cardiac care are urgently needed. We conducted a rapid literature appraisal (...) 2 MI (28). Myocardial injury in COVID-19 patients can manifest with ST-elevation in the absence of obstructive coronary artery disease (CAD). Whether this is due to microvascular injury or myocarditis is unclear. To avoid unnecessary coronary angiography during the acute illness, haemodynamically stable patients with COVID-19 and possible MI may be best managed conservatively, with invasive procedures deferred until after COVID-19 recovery. Cardiovascular implications of novel therapies Numerous